Now that shareholders have voted for the deal, Bristol-Myers Squibb faces some serious pressure to prove its Celgene buyout will actually pay off. So it's no wonder analysts are demanding to know...
In Takeda’s last quarterly report as a separate company from Shire, things seem to be going its way—key drugs are growing nicely, Shire integration is on track, and cash-raising sell-offs are underway, executives said.
Bayer completed the deal to acquire US-based Monsanto recently and the acquisition of Monsanto has been completed globally but it is still in process in India